MESO - メソブラスト (Mesoblast Limited) メソブラスト



symbol MESO
会社名 Mesoblast Ltd (メソブラスト)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 メソブラスト(Mesoblast Limited)は骨髄や脂肪組織に由来製品の間葉系前駆細胞(MPC)技術プラットフォーム、歯髄幹細胞(DPSCs)、及び拡大造血幹細胞(HSC)を含むそのコア技術を活用した臨床開発会社である。同社の心臓血管と神経製品パイプラインはTeva Pharmaceutical Industries Ltd (Teva)との提携で開発された。同社の子会社にはMesoblast Inc.、Mesoblast International SA、Mesoblast Australia Pty Ltd及びMesoblast UK Limitedを含む。   メソブラストはオ―ストラリアバイオ医薬品企業。臨床開発段階で、骨髄と脂肪組織から派生した歯髄幹細胞と造血幹細胞を含む、間葉系幹細胞テクノロジ―プラットフォ―ムを利用した再生医療に取り組む。炎症に対する静脈内での治療、脊柱の整形、心血管や神経系疾患、目の脈管疾患などの治療を焦点に研究・開発を行う。本社はメルボルン。   
本社所在地 Level 38 55 Collins Street Melbourne Victoria 3000 AUS
代表者氏名 Silviu Itescu Silviu Itescu
代表者役職名 Chief Executive Officer Executive Director
電話番号 +61 3-9639-6036
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 115人
adr_tso 6854577
EBITDA EBITDA(百万ドル) -72.20000
終値(lastsale) 7.3
時価総額(marketcap) 50038412.1
時価総額 時価総額(百万ドル) 700.86350
売上高 売上高(百万ドル) 17.34100
企業価値(EV) 企業価値(EV)(百万ドル) 722.64750
当期純利益 当期純利益(百万ドル) -35.29000
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Mesoblast limited (ADR) revenues increased from $2.4M to $17.3M. Net loss decreased 54% to $35.3M. Revenues reflect Milestone revenue increase from $500K to $13.3M Commercialization revenue increase from $1.4M to $3.6M. Lower net loss reflects Remeasurement of contingent consideratio decrease from $130K (expense) to $10.5M (income) Management and administration - Balanci decrease of 5% to $19.9M



   Mesoblast (NASDAQ:MESO) Upgraded to Buy at Zacks Investment Research  2021/11/07 05:52:44 Dakota Financial News
Zacks Investment Research upgraded shares of Mesoblast (NASDAQ:MESO) from a hold rating to a buy rating in a research note published on Wednesday morning, reports. The brokerage currently has $6.75 price objective on the stock. According to Zacks, Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its []
   Tenaya Therapeutics (NASDAQ:TNYA) and Mesoblast (NASDAQ:MESO) Financial Contrast  2021/10/24 06:42:41 Transcript Daily
Tenaya Therapeutics (NASDAQ:TNYA) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation. Analyst Ratings This is a summary of current ratings and recommmendations for Tenaya Therapeutics and Mesoblast, []
   Mesoblast Limited (NASDAQ:MESO) Receives Consensus Recommendation of Hold from Brokerages  2021/10/21 19:46:44 Dakota Financial News
Shares of Mesoblast Limited (NASDAQ:MESO) have been assigned a consensus recommendation of Hold from the seven analysts that are presently covering the stock, reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year []
   Regenerative Medicine Market Top Key Players, Industry Analysis And Forecast By 2027 | Athersys, Inc., Corline Biomedical AB, Mesoblast, Nuvasive, Inc.  2021/10/20 11:56:21 OpenPR
The global regenerative medicine market is anticipated to gain the market worth of US$ 178.62 billion by 2026, expanding at a CAGR of 31.5% during the forecast period 2020-2026. The major reasons that escalate the adoption of regenerative medicine are
   Mesoblast Ltd - ADR Shares Approach 52-Week Low - Market Mover  2021/10/12 05:46:57 iShook Finance
Mesoblast Ltd - ADR (MESO) shares closed today at 0.4% above its 52 week low of $5.52, giving the company a market cap of $734M. The stock is currently down 33.3% year-to-date, down 53.3% over the past 12 months, and up 27.5%
   Mesoblast (MESO) Q3 2021 Earnings Call Transcript  2021/06/04 01:00:33 The Motley Fool
MESO earnings call for the period ending March 31, 2021.
   Mesoblast reports FQ3 results  2021/06/03 05:34:31 Seeking Alpha
   Rheumatoid Arthritis Stem Cell Therapy Market 2031 Growth Factors and Opportunities | Mesoblast Ltd., Roslin Cells  2021/03/11 09:15:12 OpenPR
Rheumatoid arthritis stem cell therapy has been demonstrated to induce profound healing activity, halt arthritic conditions, and in many cases, reverse and regenerate joint tissue. Today, bone marrow transplant, adipose or fat-derived stem cells, and allogeneic mesenchymal stem cells (human
   Mesoblast (ASX:MSB) completes $138 million private placement  2021/03/02 00:35:00 Bourse Data
02 Mar 2021 - Mesoblast (ASX:MSB) has entered into subscription agreements for a total of $138 million private placement, led by a strategic US investor group, SurgCenter Development.
   Mesoblast takes shareholders to last chance saloon  2021/03/01 02:36:43 The Australian Financial Review
Shares in Mesoblast are suspended as its auditor warns of material uncertainty around its solvency if it cannot secure new sources of funding.
   Mesoblast readies $100m private placement  2021/02/28 06:10:31 The Australian Financial Review
Cash-strapped biotech Mesoblast has drafted in some help for its last ditch capital raising.
   Chardan Capital Stick to Their Sell Rating for Mesoblast Ltd By  2021/02/11 13:03:02
Chardan Capital Stick to Their Sell Rating for Mesoblast Ltd

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 メソブラスト MESO Mesoblast Limited)

 twitter  (公式ツイッターやCEOツイッターなど)